10 -11
November

Venture Capital & Private Equity

Investment Challenges and Opportunities in Emerging Biotech Markets

Hard Rock Hotel San Diego

What to expect

Timely information, interactive format

Real insights are shared in conversations, not lectures. That’s why our unique roundtable format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Featuring Industry Leaders and Decision Makers

Anthony Maida

Chief Clinical Officer – Translational Medicine Oncotelic Therapeutics, Inc.

Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease.  Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer.  He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc.  Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc.  Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 30 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.  Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities.  Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development.  Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.  Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat on multiple public company boards and advisory committees.  Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology.  He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society.  Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Christie Quarles

Clinical Analytics Product Marketing Manager Revvity Signals

David Crean

Managing Partner & Partner Cardiff Advisory LLC & 1004 Venture Partners

George Ng

Board Director, President & COO Calidi Biotherapeutics

George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing.
Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches.
Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics.
Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.

Glenn Guthrie

Senior Principal Clinical Solutions Strategy Revvity Signals

Igor O. Nasonkin

CEO Phythera Therapeutics

Igor Nasonkin is a Founder, Director, and Principal Investigator, with 9 years in industry (Phythera Therapeutics, Lineage Cell Therapeutics, Biotime, Bresagen) and 24 years in academia (UPitt, NIH, JHU, MIT, UM, UBC). He specialized in small molecule-based therapies modulating neurodegenerative diseases and cancer, botanical-based drugs for cancer therapeutics, cell & gene therapies (retina, brain), stem cell-based therapies, and building new projects and teams from the ground up. Igor has extensive experience in building and leading several productive & cohesive research teams, conceptualizing new ideas and research directions, grant writing (NIH, DOD, CIRM, foundation grants), manuscript writing, drafting patent applications, sponsored projects agreements, and business plans. He has written for a variety of Scientific reviewers (several journals), while being a member of the Editorial Board (several journals). His successfully funded SBIR grants include: 5R44EY027654 09/30/2017- 5/31/2019; 3 R44 EY 027654-02 S1 06/01/2019-05/31/2020

John Mattison

Former Operating Partner, Chief Medical Information Officer Arsenal Capital Partners

Klaus Simonsen

Vice President, Head of External Research & Innovation Lundbeck

Mehran Moghaddam

CEO OROX Biosciences, Inc.

Sudar Alagarsamy

Executive Director Program Management Arrowhead Pharmaceuticals

Tara Lehner

Vice President, Clinical Operations INmune Bio Inc.

Our Agenda

Private Equity, Venture Capital & Strategic Partnerships
Turning plant-derived (Chelidonium) molecules into Prescription [Rx] Multi-molecular Drug: A Novel Oncology & Anti-Inflammatory Drug MetPhyte TM PLUS

Igor O. Nasonkin,
CEO,
Phythera Therapeutics

Private Equity & Venture Capital
Collaborative Chemistry: The Business of Partnerships in Drug Innovation (Topic TBC)

Klaus Simonsen,
Vice President, Head of External Research & Innovation,
Lundbeck

Mehran Moghaddam,
CEO,
OROX Biosciences, Inc

PRESENTER:
Sudar Alagarsamy,
Executive Director Program Management,
Arrowhead Pharmaceuticals

RESENTER: Tara Lehner,
Vice President, Clinical Operations,
INmune Bio Inc.

Private Equity & Venture Capital
Navigating Financial Risks and Rewards in Biotech: Investment Trends in 2025 and Strategies for 2026

David Crean,
Managing Partner & Partner,
Cardiff Advisory LLC & 1004 Venture Partners

Private Equity & Venture Capital
Crossroads Between Life Sciences and Cryptocurrency in Investing

George Ng,
Chief Executive Officer,
Processa Pharmaceuticals

Private Equity & Venture Capital
From Oversight to Insight: Accelerating Clinical Operations with AI-Augmented Data Review

Glenn Guthrie
Senior Principal Clinical Solutions Strategy
Revvity Signals

Christie Quarles
Clinical Analytics Product Marketing Manager
Revvity Signals

Private Equity & Venture Capital
Exploring the Key Strategies for Improving the Cost-Efficiency of Clinical Trials and Increasing ROI for Investors?

John Mattison,
Operating Partner, CMIO,
Arsenal Capital Partners

Private Equity & Venture Capital
Can the Boom and Bust Cycle of Biotech Investing be Changed?

CHAIRPERSON: David Crean, Managing Partner,
Cardiff Advisory LLC | Partner,
1004 Venture Partners

PANELISTS: George Ng,
Chief Executive Officer,
Processa Pharmaceuticals

PANELISTS: John Mattison,
Former Operating Partner, Chief, Medical Information Officer,
Arsenal Capital Partners

Engage in Real Conversations That Matter

Our unique roundtable format fosters meaningful dialogue—not lectures—so you gain actionable insights from every discussion. Choose up to four roundtable sessions, each limited to 20 participants, and connect with senior-level peers in a relaxed, collaborative setting.

Choose Your Venture Date

*First name

*Last name

*Company name

*Job Title

*First line of address

*City

*Postcode/Zipcode

*Country

*Work Email

*Direct Line

*Mobile/Cell

*What are your 3 main strategic challenges?

Do you have dietary requirements?

YesNo

If yes please indicate

***We Highly Recommend to Use Google Chrome, Safari or Firefox Browser.

I hereby consent Proventa International to collect and share my provided contact details to other delegates and sponsors attending the same event I am attending.

I agree to Proventa International using this information to contact me about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy.

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Europe

R&D

Investment Dinners & Spotlights

Venture Capital & Private Equity

Venture Capital & Private Equity

Investment Challenges and Opportunities in Emerging Biotech Markets

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2012%2016'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hard Rock Hotel San Diego

Timely information, interactive format

Anthony Maida

Christie Quarles

David Crean

George Ng

Glenn Guthrie

Igor O. Nasonkin

John Mattison

Klaus Simonsen

Mehran Moghaddam

Sudar Alagarsamy

Tara Lehner

Our Agenda

Day 1 : 10th of November, 2025

Registration And Welcome

Opening Keynote Presentation Turning plant-derived (Chelidonium) molecules into Prescription [Rx] Multi-molecular Drug: A Novel Oncology & Anti-Inflammatory Drug MetPhyte TM PLUS

Roundtable Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Networking Lunch

Roundtable Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery

Topic TBC Panel Discussion

Drinks & Canapes Reception

Day 2 : 11th of November, 2025

Registration And Welcome

Opening Keynote Presentation The Future of Clinical Operations: Driving Innovation, Efficiency, and Impact

Roundtable Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Roundtable Roundtable Tracks

Networking Lunch

Networking / 1-1 Meetings

Afternoon Keynote Presentation From Oversight to Insight: Accelerating Clinical Operations with AI-Augmented Data Review

Roundtable Roundtable Tracks

Panel Discussion

Drinks & Canapes Reception

Engage in Real Conversations That Matter

You had been successfully registered.

Further Information

Here To Help

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Hard Rock Hotel San Diego